Millennium Pharmaceuticals to Acquire COR Therapeutics in $2.0 Billion Deal
- 12.7.2001
On December 6, 2001, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced that it had signed a definitive agreement to acquire COR Therapeutics, Inc. (Nasdaq: CORR) in a stock-for-stock exchange valued at $2.0 billion.
Millennium was advised by the following Hale and Dorr lawyers:
-
on corporate and securities matters, partners David Redlick, Jeff Stein and Jonathan Wolfman, junior partner Ken Lepage and associate Kris Spreen;
-
on intellectual property and licensing matters, partner Steven Singer, junior partner Michael Twomey and associates Jan Siok and Soojin Chung;
-
on tax matters, partner Rob Burke and associate Erika Buell;
-
on real estate matters, partner Keith Barnett;
-
on environmental matters, partner Rob Kirsch and associate Pat van der Voorn;
-
on employee benefits matters, partner Bill Schmidt; and
-
on immigration matters, partner Carolyn Fuchs.
